Stereoisomerism in adrenergic drugs

  • P. N. Patil
  • J. B. LaPidus
Conference paper
Part of the Ergebnisse der Physiologie, biologischen Chemie und experimentellen Pharmakologie book series (ERGEBPHYSIOL, volume 66)


Adrenergic Receptor Absolute Configuration Optical Isomer Adrenergic Neuron Ergic Neuron 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Abdallah, A. H.: Anorectic activity of ephedrine isomers. Life Sci. 7, 665–670 (1968).Google Scholar
  2. Abdallah, A. H., Tye, A., Patil, P. N.: Steric aspects of adrenergic drugs. X. Tachyphylaxis to the ephedrine isomers in the isolated rabbit heart. Arch. int. Pharmacodyn. 174, 454–468 (1968).Google Scholar
  3. Åblad, B., Brogård, M., Ek, L.: Pharmacological properties of H 56/28—a β-adrenergic receptor antagonist. Acta pharmacol. (Kbh.) 25, Suppl 2, 9–40 (1967).Google Scholar
  4. Albertson, N. F., McKay, F. C., Lape, H. E., Hoppe, J. O., Selberis, W. H., Arnold, A.: The optical isomers of metaraminol. Synthesis and biological activity. J. med. Chem. 13, 132–134 (1970).PubMedGoogle Scholar
  5. Alestig, K., Sannerstedt, R.: L-alpha-methyl-dopa versus the recemic form—a comparative study of the hypotensive effect. Acta med. scand. 179, 747–753 (1966).PubMedGoogle Scholar
  6. Alles, G. A., Knoefel, P. K.: Comparative physiological actions of phenethylamine and of the beta-hydroxyphenethylamines. Univ. Calif. Publ. Pharmacol. 1, 101–118 (1938).Google Scholar
  7. Almirante, L., Murmann, W.: Relationship between configuration and adrenergic beta-receptor blocking activity of optical isomers of 1-(4-nitrophenyl)-2-isopropyl-aminoethanol (INPEA). J. med. Chem. 9, 650–653 (1966).PubMedGoogle Scholar
  8. Ariëns, E. J.: Molecular pharmacology, p. 243. New York: Academic Press 1964.Google Scholar
  9. Ariëns, E. J.: Wirkung und Wirkungsmechanismus von Katecholmainen und ihren Derivaten. Naunyn-Schmiedebergs Arch. Pharmak. exp. Path. 257, 118–141 (1967).Google Scholar
  10. Axelrod, J.: The enzymatic deamination of amphetamine (benzedrine). J. biol. Chem. 214, 753–763 (1955).PubMedGoogle Scholar
  11. Axelrod, J.: Methylation reactions in the formation and metabolism of catecholamines and other biogenic amines. Pharmacol. Rev., part 1, 18, 95–113 (1966).PubMedGoogle Scholar
  12. Axelrod, J., Tomchick, R.: Enzymatic O-methylation of epipneprine and other catechols. J. biol. Chem. 233, 702–705 (1958).PubMedGoogle Scholar
  13. Badger, G. M.: Molecular asymmetry and biological activity. Nature (Lond.) 159, 194–196 (1947).PubMedGoogle Scholar
  14. Barlow, R. B.: Differences in the stereospecificity of closely related compounds: a reinvestigation of the enantiomers of procyclidine, benzhexol and their metho-and etho-salts. J. Pharm. Pharmacol. 23, 90–97 (1971).PubMedGoogle Scholar
  15. Barrett, A. M., Cullum, V. A.: The biological properties of the optical isomers of propranolol and their effects on cardiac arrhythmias. Brit. J. Pharmacol. 34, 43–55 (1968).Google Scholar
  16. Barrett, A. M., Nunn, B.: Adrenergic neuron blocking properties of (±)-propranolol and (+)-propranolol). J. Pharm. Pharmacol. 22, 806–810 (1970).PubMedGoogle Scholar
  17. Beckett, A. H.: Stereochemical factors in biological activity. Fortschr. Arzneimittelforsch. 1, 455–531 (1959).PubMedGoogle Scholar
  18. Beckett, A. H., Hossie, R. D.: Buccal absorption of drugs. In: Handbuch der experimentellen Pharmakologie, Bd. XXVIII/1, Hrsg. Brodie, B. B., Gillette, J. R., S. 25–46. Berlin-Heidelberg-New York: Springer 1971.Google Scholar
  19. Beckett, A. H., Kirk, G., Sharpen, A. J.: The configuration of α-methyldopamine. Tetrahedron 21, 1489–1493 (1965).Google Scholar
  20. Beckett, A. H., Rowland, M.: Urinary excretion kinetics of amphetamine in man. J. Pharm. Pharmacol. 17, 628–639 (1965a).PubMedGoogle Scholar
  21. Beckett, A. H., Rowland, M.: Urinary excretion kinetics of methylamphetamine in man. J. Pharm. Pharmacol. 17, Suppl., 109–114 (1965b).Google Scholar
  22. Beckett, A. H., Wilkinson, G. R.: Urinary excretion of (−)-methylephedrine, (−)-ephedrine and (−)-norephedrine in man. J. Pharm. Pharmacol. 17, Suppl., 107–108 (1965).Google Scholar
  23. Belleau, B.: The mechanism of drug action at receptor surfaces. Part I. Introduction. A general interpretation of the adrenergic blocking activity of β-haloalkylamines. Canad. J. Biochem. 36, 731–753 (1958).PubMedGoogle Scholar
  24. Belleau, B., Burba, J.: The stereochemistry of the enzymic decarboxylation of amino acids. J. Amer. chem. Soc. 82, 5751–5752 (1960).Google Scholar
  25. Belleau, B., Burba, J.: Effect of deuterium substitution in sympathomimetic amines on adrenergic responses. Science 133, 102–104 (1961).PubMedGoogle Scholar
  26. Belleau, B., Cooper, P.: Conformation of N-(β-chloroethyl)-2 phenoxyethylamines in relation to adrenergic blocking activity. J. med. Chem. 6, 579–583 (1963).PubMedGoogle Scholar
  27. Belleau, B., Triggle, D. J.: Blockade of adrenergic α-receptors by a carbonium ion. J. med. pharm. Chem. 5, 636–639 (1962).Google Scholar
  28. Belliveau, R. E., Covino, B. G.: Effects of a new β-adrenergic receptor blocking agent, alprenolol, and its optical isomers. Arch. int. Pharmacodyn. 180, 341–349 (1969).PubMedGoogle Scholar
  29. Bentley, R.: Molecular asymmetry in biology, vol. II. New York: Academic Press 1970.Google Scholar
  30. Benvenuti, F., Bonaccorsi, A., Garattini, S.: Potentiation of noradrenaline isomers by cocaine and desipramine in the isolated vas deferens of the rat. J. Pharm. Pharmacol. 19, 477–478 (1967).PubMedGoogle Scholar
  31. Berkowitz, B. A., Spector, S., Brossi, A., Focella, A., Teitel, S.: Preparation and biological properties of (-)-and (+)-6-hydroxydopa. Experientia (Basel) 26, 982–983 (1970).PubMedGoogle Scholar
  32. Berti, F., Shore, P. A.: Interaction of reserpine and ouabain on amine concentrating mechanisms in the adrenergic neurone. Biochem. Pharmacol. 16, 2271–2274 (1967).PubMedGoogle Scholar
  33. Blaschko, H.: A discussion on the action of local hormones. Proc. roy. Soc. B 137, 307–311 (1950).Google Scholar
  34. Blaschko, H., Holton, P., Stanley, G. H. S.: The decarboxylation of β-3:4 dihydroxyphenylserine (noradrenaline carboxylic acid). Brit. J. Pharmacol. 3, 315–319 (1948).PubMedGoogle Scholar
  35. Blaschko, H., Richter, D., Schlossmann, H.: Oxidation of adrenaline and other amines. Biochem. J. 31, 2187–2196 (1937).PubMedGoogle Scholar
  36. Blinks, J. R.: Influence of β-hydroxyl group on the inotropic and chronotropic activities of catecholamines. Pharmacologist 6, 176 (1964).Google Scholar
  37. Boakes, R. J., Bradley, P. B., Brookes, N., Candy, J. M., Wolstencroft, J. H.: Actions of noradrenaline, other sympathomimetic amines and antagonists on neurones in the brain stem of the cat. Brit. J. Pharmacol. 41, 462–479 (1971).Google Scholar
  38. Booth, D. A.: Mechanism of action of norepinephrine in eliciting an eating response on injection into the rat hypothalamus. J. Pharmacol. exp. Ther. 160, 336–348 (1968).PubMedGoogle Scholar
  39. Born, G. V. R.: Discussion remark. In: Adrenergic neurotransmission, ed. Wolstenholme, G. E. W., O’Connor, M., p. 57. Ciba foundation, Study group No 33. Boston: Little, Brown & Co. 1968.Google Scholar
  40. Born, G. V. R., Day, M., Stockbridge, A.: The uptake of amines by human erythrocytes in vitro. J. Physiol. (Lond.) 193, 405–418 (1967).PubMedGoogle Scholar
  41. Brodie, B. B., Cho, A. K., Gessa, G. L.: Possible role of p-hydroxynorephedrine in the depletion of norepinephrine induced by d-amphetamine and intolerance to this drug. Amphetamine an drelated compounds, p. 217–230 (ed. by Costa, E., Garattini, S.). Milan (Italy): Raven Press 1970.Google Scholar
  42. Buchthal, A. B., Jenkinson, D. H.: Effects of isomers of the α-antagonist amidephrine on arterial and tracheal muscle in vitro. Europ. J. Pharmacol. 10, 293–296 (1970).Google Scholar
  43. Buckner, C. K.: Beta adrenergic receptors of guinea-pig atria and trachea: use of isomeric-activity-differences of agonists and antagonists to characterize pharmacological receptors. Ph. D. dissertation The Ohio State University 1970.Google Scholar
  44. Buckner, C. K., Patil, P. N.: Steric aspects of adrenergic drugs. XVI. Beta adrenergic receptors of guinea-pig atria and trachea. J. Pharmacol. exp. Ther. 176, 634–649 (1971).PubMedGoogle Scholar
  45. Buckner, C. K., Patil, P. N., Tye, A., Malspeis, L.: Steric aspects of adrenergic drugs. XII. Some peripheral effects of (±)-erythro-and (±)-threo-methylphenidate. J. Pharmacol. exp. Ther. 166, 308–319 (1969).PubMedGoogle Scholar
  46. Burgen, A. S. V., Iversen, L. L.: The inhibition of noradrenaline uptake by sympathomimetic amines in the rat isolated heart. Brit. J. Pharmacol. 25, 34–49 (1965).PubMedGoogle Scholar
  47. Burgin, R.: The molecular structure of some sympathomimetic amines and related substances. A Bulletin (1971) from the department of medical physics Karolinska Institute, Stockholm 60, Sweden.Google Scholar
  48. Burkman, A. M., Yamauchi, D., Hetey, S., Patil, P. N.: Sympathomimetic effects of apomorphine inrelationship to the proposed dopamine receptor (unpublished report) (1972).Google Scholar
  49. Cahn, R. S.: An introduction to the sequence rule. A system for the specification of absolute configuration. J. Chem. Educ. 41, 116–125 (1964).Google Scholar
  50. Carlsson, A., Meisch, J., Waldeck, B.: On the β-hydroxylation of (±)-α-methyldopamine in vivo. Europ. J. Pharmacol. 5, 85–92 (1968).Google Scholar
  51. Carlsson, A., Waldeck, B.: Structure-activity relationships for release of 14C-octopamine from adrenergic nerves by phenylethylamines. Acta pharmacol. (Kbh.) 24, 255–262 (1966).Google Scholar
  52. Chen, K. K., Wu, C. K., Henriksen, E.: Relationship between the pharmacological action and the chemical constitution and configuration of the optical isomers of ephedrine and related compounds. J. Pharmacol. exp. Ther. 36, 363–401 (1929).Google Scholar
  53. Cohen, P. Y., Janiec, W., Bralet, J.: Influence des isomeres optiques d’un inhibiteur β-adrenergique, la N-isopropyl-para-nitrophenylethanolamine (INPEA) sur la fixation tissulaire et la metabolisme de l’adrenaline 14C chez le rat. Therapie 23, 635–648 (1968).PubMedGoogle Scholar
  54. Coyle, J. T., Snyder, S. H.: Catecholamine uptake by synaptosomes in homogenates of rat brain: Stereospecificity in different areas. J. Pharmacol. exp. Ther. 170, 221–231 (1969).PubMedGoogle Scholar
  55. Creveling, C. R., Dalgard, N., Shimizu, H., Daly, J. W.: Catechol O-methyltransferase. III. m-and p-methylation of catecholamines and their metabolites. Molec. Pharmacol. 6, 691–696 (1970).Google Scholar
  56. Creveling, C. R., Daly, J., Tokuyama, T., Witkop, B.: The combined use of α-methyltyrosine and threo-dihydroxyphenylserine—selective reduction of dopamine levels in the central nervous system. Biochem. Pharmacol. 17, 65–70 (1968).PubMedGoogle Scholar
  57. Cushny, A. R.: “Pharmacology and therapeutics.” Biological relations of optically isomeric substances. Baltimore, Maryland: William & Wilkins Co. 1926.Google Scholar
  58. Daly, J. W., Creveling, C. R., Witkop, B.: The chemorelease of norepinephrine from mouse hearts. Structure-activity relationships. I. Sympathomimetic and related amines. J. med. Chem. 9, 273–280 (1966).PubMedGoogle Scholar
  59. Dann, R.: Approaches to the study of the metabolism of the optical isomers of ephedrine. M.S. thesis The Ohio State University 1968.Google Scholar
  60. Davis, W. G.: The reversal of phenoxybenzamine-produced α-adrenoceptor blockade by the isomers of propranolol and INPEA. J. Pharm. Pharmacol. 23, 332–338 (1971).PubMedGoogle Scholar
  61. Dewhurst, W. G., Marley, E.: The effects of α-methyl derivatives of noradrenaline, phenylethylamine and tryptamine on the central nervous system of the chicken. Brit. J. Pharmacol. 25, 682–704 (1965a).PubMedGoogle Scholar
  62. Dewhurst, W. G., Marley, E.: Action of sympathomimetic and allied amines on the central nervous system of the chicken. Brit. J. Pharmacol. 25, 705–727 (1965b).PubMedGoogle Scholar
  63. Dohadwalla, A. N., Freedberg, A. S., Vaugham-Williams, E. M.: The relevance of β-receptor blockade to ouabain-induced cardiac arrhythmias. Brit. J. Pharmacol. 36, 257–267 (1969).Google Scholar
  64. Draskóczy, P. R., Trendelenburg, U.: The uptake of 1-and d-norepinephrine by the isolated perfused rabbit heart in relation to the stereospecificity of the sensitizing action of cocaine. J. Pharmacol. exp. Ther. 159, 66–73 (1968).PubMedGoogle Scholar
  65. Drews, E.-F., Lindmar, R., Muscholl, E.: Noradrenaline depleting and blood pressure lowering activity of threo-corbadrine. Europ. J. Pharmacol. 3, 167–169 (1968).Google Scholar
  66. Dring, L. G., Smith, R. L., Williams, R. T.: The fate of amphetamine in man and other mammals. J. Pharm. Pharmacol. 18, 402–405 (1966).PubMedGoogle Scholar
  67. Dring, L. G., Smith, R. L., Williams, R. T.: The metabolic fate of amphetamine in man and other species. Biochem. J. 116, 425–435 (1970).PubMedGoogle Scholar
  68. Dubnick, B., Rucki, E. W.: Selective lowering of brain serotonin by p-acylphenyl-ethylamines. Europ. J. Pharmacol. 12, 280–288 (1970).Google Scholar
  69. Duce, B. R., Garberg, L., Johansson, B.: The effect of propranolol and the dextro and laevo isomers of H 56/28 upon ouabain-induced ventricular tachycardia in unanaesthetized dogs. Acta pharmacol. (Kbh.) 25, Suppl. 2, 41–49 (1967).Google Scholar
  70. Duce, B. R., Garberg, L., Smith, E. R.: Effects of (±)-propranolol, (±)-and (+)-, and (-)-alprenolol on unanaesthetized dogs with ventricular arrhythmias resulting from coronary artery ligation. Brit. J. Pharmacol. 39, 809–816 (1970).Google Scholar
  71. Dukes, M., Smith, L. H.: β-Adrenergic blocking agents. 9. Absolute configuration of propranolol and of a number of related aryloxypropanolamines and arylethanolamines. J. med. Chem. 14, 326–328 (1971).PubMedGoogle Scholar
  72. Dvornik, D., Schilling, G.: Stereochemistry of d-3,4-dimethyl-2-phenylmorpholine (Phendimetrazine). J. med. Chem. 8, 466–469 (1965).PubMedGoogle Scholar
  73. Easson, L. H., Stedman, E.: CLXX. Studies on the relationship between chemical constitution and physiological action. V. Molecular dissymmetry and physiological activity. Biochem. J. 27, 1257–1266 (1933).PubMedGoogle Scholar
  74. Effland, R.: Synthetic and pharmacological studies of agents affecting peripheral adrenergic activity. Ph.D. Dissertation The Ohio State University 1971.Google Scholar
  75. Eliel, E. L.: Stereochemistry of carbon compounds, p. 87–95. New York: McGraw-Hill 1962.Google Scholar
  76. Euler, U. S. v.: Identification of sympathomimetic ergone in adrenergic nerves of cattle (sympathin N) with laevo-noradrenaline. Acta physiol. scand. 16, 63–74 (1948).Google Scholar
  77. Euler, U. S. v., Lishajko, F.: Uptake of L-and D-isomers of catecholamines in adrenergic nerve granules. Acta physiol. scand. 60, 217–222 (1964).Google Scholar
  78. Euler, U. S. v., Lishajko, F.: Stereospecific catecholamine uptake in rabbit hearts depleted by decaborane. Int. J. Neuropharmacol. 4, 273–280 (1965).Google Scholar
  79. Euler, U. S. v., Lishajko, F.: Reuptake and net uptake of noradrenaline in adrenergic nerve granules with a note on the affinity for 1-and d-isomers. Acta physiol. scand. 71, 151–162 (1967).Google Scholar
  80. Euler, U. S. v., Lishajko, F.: Inhibitory action of adrenergic blocking agents on reuptake and net uptake of noradrenaline in nerve granules. Acta physiol. scand. 74, 501–506 (1968).Google Scholar
  81. Fairchild, M. D., Alles, G. A.: The central locomotor stimulatory activity and acute toxicity of the ephedrine and norephedrine isomers in mice. J. Pharmacol. exp. Ther. 158, 135–139 (1967).PubMedGoogle Scholar
  82. Farrugia, M. T., Hunter, W. H., Kirk, G.: The preparation and pharmacological properties of ψ-corbasil. J. Pharm. Pharmacol. 21, Suppl., 199–205 (1969).Google Scholar
  83. Feller, D. R., Malspeis, L.: Metabolism of D(−)-ephedrine and L(+)-ephedrine in the microsomal and 9000 × g supernatant fractions of rabbit liver. Fed. Proc. 30, 225 (1971).Google Scholar
  84. Ferrini, R., Miragoli, G., Croce, G.: The pharmacological actions of butidrine. A comparative study of this new β-adrenergic receptor antagonist and its four stereoisomers. Arzneimittel-Forsch. 18, 829–833 (1968).Google Scholar
  85. Fielden, R., Green, A. L.: Studies on the antagonism between the optical isomers of N-(1-phenylethyl)guanidine. Brit. J. Pharmacol. 26, 264–270 (1966).PubMedGoogle Scholar
  86. Fielden, R., Green, A. L.: Optical isomers of β-hydroxyphenethylguanidine: effects on heart noradrenaline and on sympathetic blockade. Brit. J. Pharmacol. 32, 350 (1968).PubMedGoogle Scholar
  87. Foo, J. W., Jowett, A., Stafford, A.: The effects of some β-adrenoreceptor blocking drugs on the uptake and release of noradrenaline by the heart. Brit. J. Pharmacol. 34, 141–147 (1968).Google Scholar
  88. Fuller, R. W., Hines, C. W., Mills, J.: Lowering of brain serotonin level by chloroamphetamines. Biochem. Pharmacol. 14, 483–488 (1965a).PubMedGoogle Scholar
  89. Fuller, R. W., Walters, C. P.: Inhibition of monoamine oxidase action on kynuramine by substrate amines and stereoisomeric α-methyl amines. Biochem. Pharmacol. 14, 159–163 (1965b).PubMedGoogle Scholar
  90. Garg, B., Buckner, C., Sethi, O., Sokoloski, T., Patil, P. N.: Steric aspects of adrenergic drugs. XVII. Influence of tropolone on the magnitude and duration of action of catecholamine isomers. Arch. int. Pharmacodyn. 189, 281–294 (1971).PubMedGoogle Scholar
  91. Gerald, M. C., Riffee, W. H.: The effect of d and l amphetamine on pentylenetetrazol induced seizures in mice. Pharmacologist 13, 204 (1971).Google Scholar
  92. Giachetti, A., Shore, P. A.: Intracellular distribution of metaraminol and related compounds in rat heart. Life Sci. 4, 1455–1460 (1965).PubMedGoogle Scholar
  93. Giachetti, A., Shore, P. A.: Optical specificity of monoamine oxidase. Life Sci. 5, 1373–1378 (1966).PubMedGoogle Scholar
  94. Gilfrich, H. J., Rahn, K. H., Schmahl, F. W.: A comparison of the antihypertensive action of propranolol and the optical isomers of n-isopropyl-p-nitrophenylethanol-amine (INPEA). Pharmacol. Clin. 2, 30–33 (1969).Google Scholar
  95. Gillespie, J. S., Hamilton, D. N. H., Hosie, R. J. A.: The extraneuronal uptake and localization of noradrenaline in the cat spleen and the effect on this of some drugs, of cold and of denervation. J. Physiol. (Lond.) 206, 563–590 (1970).PubMedGoogle Scholar
  96. Goldberg, L. I., Sonneville, P. F., McNay, J. L.: An investigation of the structural requirements for dopamine-like renal vasodilation: phenylethylamines and apomorphine. J. Pharmacol. exp. Ther. 163, 188–197 (1968).PubMedGoogle Scholar
  97. Goldstein, M., Anagnoste, B.: The conversion in vivo of D-amphetamine to (+)-p-hydroxynorephedrine. Biochim. biophys. Acta (Amst.) 107, 166–168 (1965).PubMedGoogle Scholar
  98. Gordis, E.: Gas-chromatographic resolution of optical isomers in microgram samples of amphetamine. Biochem. Pharmacol. 15, 2124–2126 (1966).PubMedGoogle Scholar
  99. Graefe, K. H., Bonisch, H., Trendelenburg, U.: Time-dependent changes in neuronal net uptake of noradrenaline after pretreatment with pargyline and/or reserpine. Naunyn-Schmiedebergs Arch. Pharmak. 271, 1–28 (1971).Google Scholar
  100. Graefe, K. H., Trendelenburg, U.: The effect of cocaine on uptake of and sensitivity to noradrenaline in isolated nictitating membranes before and after storage in the cold. Naunyn-Schmiedebergs Arch. Pharmak. 267, 383–398 (1970).Google Scholar
  101. Grana, E., Lilla, L.: The inhibition of amine oxidase and the central stimulating action of the stereoisomeric amphatemines and 1-phenylethylamines. Brit. J. Pharmacol. 14, 501–504 (1959).PubMedGoogle Scholar
  102. Green, R. D., III, Fleming, W. W.: Analysis of supersensitivity in the isolated spleen of the cat. J. Pharmacol. exp. Ther. 162, 254–262 (1968).PubMedGoogle Scholar
  103. Gunne, L. M.: The urinary output of d-and 1-amphetamine in man. Biochem. Pharmacol. 16, 863–869 (1967).PubMedGoogle Scholar
  104. Hartley, D., Middlemiss, D.: Absolute configuration of the optical isomers of salbutamol. J. med. Chem. 14, 895–896 (1971).Google Scholar
  105. Hendley, E. D., Snyder, S. H.: Stereoselectivity of the uptake of H3-(±)-norepinephrine in noradrenergic and dopaminergic peripheral organs of the rabbit. Fed. Proc. 30, 445 (1971a).Google Scholar
  106. Hendley, E. D., Snyder, S. H., Fauley, J. J., LaPidus, J. B.: Stereoselectivity of catecholamine uptake in rat brain synaptosomes: Studies with ephedrine, phenyl-2-piperidyl carbanol and methylphenidate stereosiomers. Pharmacologist 13, 203 (1971).Google Scholar
  107. Hendley, E. D., Taylor, K. M., Snyder, S. H.: 3H-normetanephrine uptake in rat brain slices. Relationship to extraneuronal accumulation of norepinephrine. Europ. J. Pharmacol. 12, 167–179 (1970).Google Scholar
  108. Henning, M., Van Zwieten, P. A.: Central hypotensive effect of α-methyldopa. J. Pharm. Pharmacol. 20, 409–417 (1968).PubMedGoogle Scholar
  109. Hermansen, K.: Effect of different β-adrenergic receptor blocking agents on hexobarbital induced narcosis in mice. Acta pharmacol. (Kbh.) 27, 453–460 (1969).Google Scholar
  110. Hewick, D. S., Fouts, J. R.: The metabolism in vitro and hepatic microsomal interactions of some enantiomeric drug substrates. Biochem. J. 117, 833–841 (1970).PubMedGoogle Scholar
  111. Hoffmann, H.: Vergleichende Untersuchungen anorexigener und zentralstimulierender Eigenschaften einiger Phenmetrazin-und Ephedrinderivate. Arch. int. Pharmacodyn. 160, 180–187 (1966).PubMedGoogle Scholar
  112. Howe, R., Rao, B. S.: β-Adrenergic blocking agents. III. The optical isomers of pronethalol, propranolol and several related compounds. J. med. Chem. 11, 1118–1120 (1968).PubMedGoogle Scholar
  113. Howe, R., Shanks, R. G.: Optical isomers of propranolol. Nature (Lond.) 210, 1336–1338 (1966).PubMedGoogle Scholar
  114. Iversen, L. L.: The uptake of noradrenaline by the isolated perfused rat heart. Brit. J. Pharmacol. 21, 523–537 (1963).PubMedGoogle Scholar
  115. Iversen, L. L.: The uptake of adrenaline by the rat isolated heart. Brit. J. Pharmacol. 24, 387–394 (1965).PubMedGoogle Scholar
  116. Iversen, L. L.: Role of transmitter uptake mechanisms in synpatic neurotransmission. Brit. J. Pharmacol. 41, 571–591 (1971).Google Scholar
  117. Iwasawa, Y., Kiyomoto, A.: Studies on tetrahydroisoquinolines (THI) (I) bronchodilator activity and structure-activity relationship. Jap. J. Pharmacol. 17, 143–152 (1967).PubMedGoogle Scholar
  118. Janiec, W., Chrusciel, T. L.: The effect of the optical isomer of N-1-(4′-nitrophenyl)-2-isopropyl-ethanolamine (INPEA) on the uptake of 3H-norepinephrine by the cardiac muscle of the rat in vitro. Arch. int. Pharmacodyn. 180, 255–263 (1969).PubMedGoogle Scholar
  119. Kaplan, H. R., Robson, R. D.: Antiarhythmic activity of bunolol, a new beta adrenergic blocking agent. J. Pharmacol. exp. Ther. 175, 168–177 (1970).PubMedGoogle Scholar
  120. Katz, R. L., Lord, C. O., Eakins, K. E.: Anesthetic-dopamine cardiac arrhythmias and their prevention by beta adrenergic blockade. J. Pharmacol. exp. Ther. 158, 40–45 (1967).PubMedGoogle Scholar
  121. Kelliher, G. J., Buckley, J. P.: Central hypotensive activity of dl-and d-propranolol. J. Pharm. Sci. 59, 1276–1280 (1970).PubMedGoogle Scholar
  122. Kier, L. B.: The preferred conformation of norepinephrine and a consideration of the α-adrenergic receptor. J. Pharm. Pharmacol. 22, 93–96 (1969).Google Scholar
  123. Kilbinger, H., Lindmar, R., Löfelholz, K., Muscholl, E., Patil, P. N.: Storage and release of false transmitters after infusion of (+)-and (−)-α-methyldopamine. Naunyn-Schmiedebergs Arch. Pharmak. 271, 234–248 (1971).Google Scholar
  124. Kirpekar, S. M., Wakade, A. R.: Factors influencing noradrenaline uptake by the perfused spleen of the cat. J. Physiol. (Lond.) 194, 609–626 (1968).PubMedGoogle Scholar
  125. Knoll, J., Vizi, E. S., Somogyi, G.: Phenylisopropylmethylpropynylamine (E-250), a monoaminooxidase inhibitor antagonising the effects of tyramine. Arzneimittel-Forsch. 18, 109–112 (1968).Google Scholar
  126. Koch, M. V., Cannon, J. G., Burkman, A. M.: Centrally acting emetics. II. Norapomorphine and derivatives. J. med. Chem. 11, 977–981 (1968).PubMedGoogle Scholar
  127. Kopin, I. J., Bridgers, W.: Differences in D-and L-norepinephrine-H3. Life Sci. 2, 356–362 (1963).Google Scholar
  128. Kraupp, O., Bernheimer, H., Ehringer, H., Heistracher, P.: O-Methylierung und N-Demethylierung im Verlauf des Adrenalinabbaues bei der Ratte. Naunyn-Schmiedebergs Arch. exp. Path. Pharmak. 238, 38–39 (1960).Google Scholar
  129. Krell, R., Patil, P. N.: Steric aspects of adrenergic drugs XIX. Influence of various agents and procedures on the stero-selectivity of pre-and post-junctional sites to norepinephrine isomers. J. Pharmacol. exp. Ther. 182, 101–115 (1972).PubMedGoogle Scholar
  130. La Manna, A, Pratesi, P., Conte, U., Ghislandi, V.: Sintesi E configurazione della DL Threo-3,4 diossinorephedrina. Farmaco (Pavia) Ed. Sci. 22, 667–680 (1967).Google Scholar
  131. Lanciault, G., Wolf, H. H.: Some neuropharmacological properties of the ephedrine isomers. J. pharm. Sci. 54, 841–844 (1965).PubMedGoogle Scholar
  132. Lands, A. M., Luduena, F. P., Tullar, B. F.: The pharmacologic activity of the optical isomers of isopropylarterenol (Isuprel) compared with that of the optically inactive analog 1-(3,4-dihydroxyphenyl)-2-isopropylaminoethane HCl. J. Pharmacol. exp. Ther. 111, 469–474 (1954).PubMedGoogle Scholar
  133. Langer, S. Z., Trendelenburg, U.: The effect of a saturable uptake mechanism on the slopes of dose-response curves for sympathomimetic amines and on the shifts of dose-response curves produced by a competitive antagonist. J. Pharmacol. exp. Ther. 167, 117–142 (1969).PubMedGoogle Scholar
  134. LaPiuds, J. B., Tye, A., Patil, P., Modi, B. A.: Conformational aspects of drug action. I. The effects of D(—)-pseudoephedrine on the action of certain pressor amines. J. med. Chem. 6, 76–77 (1963).Google Scholar
  135. LaPidus, J. B., Tye, A., Patil, P. N.: Steric aspects of adrenergic drugs. VII. Certain pharmacological actions of D(—)-pseudoephedrine. J. Pharm. Sci. 56, 1125–1130 (1967).PubMedGoogle Scholar
  136. Levy, J. V., Richards, V.: Inotropic and chronotropic effects of a series of β-adrenergic blocking drugs: some structure-activity relationships. Proc. Soc. exp. Biol. (N.Y.) 122, 373–379 (1966).PubMedGoogle Scholar
  137. Lewander, T.: On the presence of p-hydroxynorephedrine in the rat brain and heart in relation to changes in catecholamine levels after administration of amphetamine. Acta pharmacol. (Kbh.) 29, 33–48 (1974).Google Scholar
  138. Lindmar, R., Muscholl, E., Sprenger, E.: Funktionelle Bedeutung der Freisetzung von Dihydroxyephedrin und Dihydroxypseudoephedrin als „falschen“ sympathischen Übertragerstoffen am Herzen. Naunyn-Schmiedebergs Arch. Pharmak. exp. Path. 256, 1–25 (1967).Google Scholar
  139. Lish, P. M., Weikel, J. H., Dungan, K. W.: Pharmacological and toxicological properties of two new β-adrenergic receptor antagonists. J. Pharmacol. exp. Ther. 149, 161–173 (1965).PubMedGoogle Scholar
  140. Lord, C. O., Katz, R. L., Eakins, K. E.: Antiarrhythmic properties of stereosiomers of a beta-adrenergic agent (H 56/28). Anesthesiology 29, 288–294 (1968).PubMedGoogle Scholar
  141. Lucchesi, B. R.: The effects of pronethalol and its dextro isomer upon experimental cardiac arrhythmias. J. Pharmacol. exp. Ther. 148, 94–99 (1965).PubMedGoogle Scholar
  142. Luduena, F. P.: Smooth muscle contracting effects of levo-N-isopropyl arterenol and adrenolytic action of its dextro-isomer. Arch. int. Pharmacodyn. 137, 155–165 (1962).PubMedGoogle Scholar
  143. Lundborg, P., Stitzel, R.: Stereospecificity and intracellular binding of metaraminol. Acta physiol. scand. 72, 392–395 (1968).PubMedGoogle Scholar
  144. Lyle, G. G., Gaffield, W.: Rotary dispersion studies. III. The cinchona alkaloids. Tetrahedron Lett. No 21, 1371–1378 (1963).Google Scholar
  145. Mackenna, B. R.: Uptake of catecholamines by the hearts of rabbits treated with segontin. Acta physiol. scand. 63, 413–422 (1965).PubMedGoogle Scholar
  146. Madan, B. R., Mishra, S. N., Khanna, V. K.: Effect of dextro and laevo rotatory isomers of H 56/28 on experimental ventricular arrhythmias. Arch. int. Pharmacodyn. 182, 121–129 (1969).PubMedGoogle Scholar
  147. Magyar, K., Vizi, E. S., Ecseri, Z., Knoll, J.: Comparative pharmacological analysis of the optical isomers of phenylisopropyl-methylpropinylamine (E-250). Acta physiol. Acad. Sci. hung. 32, 377–387 (1967).PubMedGoogle Scholar
  148. Maickel, R. P., Beaven, M. A., Brodie, B. B.: Implications of uptake and storage of norepinephrine by sympathetic nerve endings. Life Sci. 2, 953–958 (1963).Google Scholar
  149. Malik, K. U.: Effect of (±) dihydroxy ephedrine and (±) dihydroxy pseudoephedrine on adrenergic transmission in mesenteric arteries. Brit. J. Pharmacol. 41, 352–360 (1971).Google Scholar
  150. Malik, K. U., Muscholl, E.: Effect of sympathomimetic amines on the response of the perfused mesenteric artery preparation to adrenergic nerve stimulation. Arzneimittel-Forsch. 19, 1574–1579 (1969).Google Scholar
  151. Margules, D. L.: Alpha-adrenergic receptors in hypothalamus for the suppression of feeding behavior by satiety. J. comp. physiol. Psychol. 73, 1–12 (1970).PubMedGoogle Scholar
  152. Marsh, D. F., Herring, D. A.: The comparative pressor activity of the optical isomers of cyclohexylisopropylamine and cyclohexylisopropylmethylamine. 9. J. Pharmacol. exp. Ther. 97, 68–71 (1949).PubMedGoogle Scholar
  153. Mathew, M., Palenik, G. J.: The crystal structure of dl-isoproterenol sulfate dihydrate. J. Amer. chem. Soc. 93, 497–502 (1971).Google Scholar
  154. Maxwell, R. A., Chaplin, E., Eckhardt, S. B., Soares, J. R., Hite, G.: Conformational similarities between molecular models of phenethylamine and of potent inhibitors of the uptake of trititated norepinephrine by adrenergic nerves in rabbit aorta. J. Pharmacol. exp. Ther. 173, 158–165 (1970).PubMedGoogle Scholar
  155. Maxwell, R. A., Keenan, P. D., Chaplin, E., Roth, B., Eckhardt, S. B.: Molecular features affecting the potency of tricyclic antidepressants and structurally related compounds as inhibitors of the uptake of tritiated norepinephrine by rabbit aortic strips. J. Pharmacol. exp. Ther. 166, 320–329 (1969).PubMedGoogle Scholar
  156. Meshi, T., Otsuka, M., Sato, Y.: Studies on trimetoquinol. I. Distribution, excretion and metabolism of trimetoquinol. Biochem. Pharmacol. 19, 2937–2948 (1970).PubMedGoogle Scholar
  157. McMahon, R. E., Sullivan, H. R.: Microsomal hydroxylation of ethylbenzene. Stereospecificity and the effect of phenobarbital induction. Life Sci. 5, 921–926 (1966).PubMedGoogle Scholar
  158. McNeill, J. H., Brody, T. M.: The effect of d-and l-norepinephrine on rat cardiac phosphorylase activation. J. Pharmacol. exp. Ther. 165, 97–101 (1969).PubMedGoogle Scholar
  159. Moore, K. E.: Toxicity and catecholamine releasing actions of d-and l-amphatemine in isolated and aggregated mice. J. Pharmacol. exp. Ther. 142, 6–12 (1963).PubMedGoogle Scholar
  160. Morgan, C. D., Löfstrandh, S., Costa, E.: Amphetamine analogues and brain amines. Pharmacologist 13, 202 (1971).Google Scholar
  161. Mueller, R. A., Shideman, F. E.: The stereospecificity of noradrenaline uptake by cat atria. J. Pharm. Pharmacol. 19, 398–400 (1967).PubMedGoogle Scholar
  162. Murad, F., Chi, Y., Rall, T. W., Sutherland, E. W.: Adenyl cyclase. III. The effect of catecholamines and choline esters on the formation of adenosine 3′,5′-phosphate by preparations from cardiac muscle and liver. J. biol. Chem. 237, 1233–1238 (1962).PubMedGoogle Scholar
  163. Murmann, W., Almirante, L., Saccani-Guelfi, M.: Central nervous system effects of four β-adrenergic receptor blocking agents. J. Pharm. Pharmacol. 13, 317–318 (1966).Google Scholar
  164. Muscholl, E.: Release of catecholamines from the heart. Mechanisms of release of biogenic amines. Proc. of an Internat. Wenner-Gren Symposium, p. 247–260 (ed. by Euler, U. S. von, Rosell, S., Uvnäs, B. Vol.) 5. Pergamon Press 1966.Google Scholar
  165. Muscholl, E., Drews, E. F., Lindmar, R.: Aufnahme von threo-Corbadrin und seine Freisetzung als falsche sympathische Überträgersubstanz. Naunyn-Schmiedebergs Arch. Pharmak. exp. Path. 260, 180 (1968).Google Scholar
  166. Muscholl, E., Sprenger, E.: Vergleichende Untersuchung der Blutdruckwirkung, Aufnahme und Speicherung von Dihydroxyephedrin (α-Methyladrenalin) und Dihydroxypseudoephedrin. Naunyn-Schmiedebergs Arch. Pharmak. exp. Path. 254, 109–124 (1966).Google Scholar
  167. Muscholl, E., Weber, E.: Die Hemmung der Aufnahme von α-Methylnoradrenalin in das Herz durch sympathomimetische Amine. Naunyn-Schmiedebergs Arch. exp. Path. Pharmak. 252, 134–143 (1965).Google Scholar
  168. Nagase, Y., Baba, S., Matsuda, A.: Studies on the analysis of drugs by use of isotopes. IV. Reverse dilution analysis of the metabolites of 14C-ephedrine. J. pharm. Soc. Jap. 87, 123–128 (1967).Google Scholar
  169. Nash, C. W., Wolff, S. A., Ferguson, B. A.: Release of tritiated noradrenaline from perfused rat hearts by sympathomimetic amines. Canad. J. Physiol. Pharmacol. 46, 35–42 (1968).Google Scholar
  170. Nelson, W. L., Miller, D. D.: Tricyclic norephedrine analogs. The isomeric 9-hydroxy-10-amino-1,2,3,4,4a,9,10,10a-(trans-4a,10a)-octahydrophenanthrenes. J. med. Chem. 13, 807–814 (1970).PubMedGoogle Scholar
  171. Nielsen, C. K., Magnussen, M. P., Kampmann, E., Frey, H. H.: Pharmacological properties of racemic and optically active p-chloroamphetamine. Arch. int. Pharmacodyn. 170, 428–444 (1967).PubMedGoogle Scholar
  172. Obianwu, H.: Actions of prenylamine (Segontin®) on the cardiovascular system. Acta pharmacol. (Kbh.) 25, 127–140 (1967).Google Scholar
  173. Ogston, A. G.: Interpretation of experiments on metabolic processes, using isotopic tracer elements. Nature (Lond.) 162, 963 (1948).PubMedGoogle Scholar
  174. Osten, W.: Phenyl-aethanol-amin und homologe Verbindungen. Arzneimittel-Forsch. 5, 84–87 (1955).Google Scholar
  175. Parmley, W. W., Braunwald, E.: Comparative myocardial depressant and anti-arrhythmic properties of d-propranolol, dl-propranolol and quinidine. J. Pharmacol. exp. Ther. 158, 11–21 (1967).PubMedGoogle Scholar
  176. Patel, A. R., Burger, A.: 3,4-Dihydroxyphenylalanine and related compounds. Fortschr. Arzneimittelforsch. 9, 224–298 (1966).Google Scholar
  177. Patil, P. N.: Steric aspects of adrenergic drugs. VIII. Optical isomers of beta adrenergic receptor antagonists. J. Pharmacol. exp. Ther. 160, 308–314 (1968).PubMedGoogle Scholar
  178. Patil, P. N.: A use of isomeric ratio as a criterion to differentiate adrenergic receptors. J. Pharm. Pharmacol. 21, 628–629 (1969).PubMedGoogle Scholar
  179. Patil, P. N., Fudge, K., Jacobowitz, D.: Steric aspects of adrenergic drugs. XVIII. Alpha adrenergic receptors of mammalian aorta. Europ. J. Pharmacol. 19, 79–87 (1972).Google Scholar
  180. Patil, P. N., Jacobowitz, D.: Steric aspects of adrenergic drugs. IX. Pharmacologic and histochemical studies on isomers of cobefrin (α-methylnorepinephrine). J. Pharmacol. exp. Ther. 161, 279–295 (1968).PubMedGoogle Scholar
  181. Patil, P. N., LaPiuds, J. B., Campbell, D., Tye, A.: Steric aspects of adrenergic drugs. II. Effects of DL isomers and desoxy derivatives on the reserpine-pretreated vas deferens. J. Pharmacol. exp. Ther. 155, 13–23 (1967a).PubMedGoogle Scholar
  182. Patil, P. N., LaPidus, J. B., Tye, A.: Steric aspects of adrenergic drugs. I. Comparative effects of DL isomers and desoxy derivatives. J. Pharmacol. exp. Ther. 155, 1–12 (1967b).PubMedGoogle Scholar
  183. Patil, P. N., Patel, D. G., Krell, R. D.: Steric aspects of adrenergic drugs. XV. Use of isomeric activity ratio as a criterion to differentiate adrenergic receptors. J. Pharmacol. exp. Ther. 176, 622–633 (1971).PubMedGoogle Scholar
  184. Patil, P. N., Patel, D. G., Tye, A.: Steric aspects of adrenergic drugs. XIV. Actions and interactions of “indirectly” acting L(+)-isomers and desoxy derivatives of sympathomimetic amines. Arch. int. Pharmacodyn. 182, 32–43 (1969).PubMedGoogle Scholar
  185. Patil, P. N., Tye, A., LaPidus, J. B.: A pharmacological study of the ephedrine isomers. J. Pharmacol. exp. Ther. 148, 158–168 (1965).PubMedGoogle Scholar
  186. Patil, P. N., Tye, A., May, C., Hetey, S., Miyagi, S.: Steric aspects of adrenergic drugs. XI. Interactions of dibenamine and beta adrenergic blockers. J. Pharmacol. exp. Ther. 163, 309–319 (1968).PubMedGoogle Scholar
  187. Pedersen, L., Hoskins, R. E., Cable, H.: The preferred conformation of noradrenaline. J. Pharm. Pharmacol. 23, 216–218 (1971).PubMedGoogle Scholar
  188. Pettinger, W. A., Spector, S., Horwitz, D., Sjoerdsma, A.: Restoration of tyramine pressor responses in reserpine-treated animals by methyldopa and its amine metabolites. Proc. Soc. exp. Biol. (N.Y.) 118, 988–993 (1965).PubMedGoogle Scholar
  189. Pfeiffer, C. C.: Optical isomerism and pharmacological action, a generalization. Science 124, 29–31 (1956).PubMedGoogle Scholar
  190. Porter, C. C., Totaro, J. A., Burcin, A., Wynosky, E. R.: The effect of the optical isomers of α-methyl-p-tyrosine upon brain and heart catecholamines in the mouse. Biochem. Pharmacol. 15, 583–590 (1966).PubMedGoogle Scholar
  191. Portoghese, P. S.: Stereochemical studies on medicinal agents. IV. Conformational analysis of ephedrine isomers and related compounds. J. med. Chem. 10, 1057–1063 (1967).PubMedGoogle Scholar
  192. Portoghese, P. S., Pazdernik, T. L., Kuhn, W. L., Hite, G., Shafi’ee, A.: Stereochemical studies on medicinal agents. V. Synthesis, configuration, and pharmacological activity of pipradrol enantiomers. J. med. Chem. 11, 12–15 (1968).PubMedGoogle Scholar
  193. Portoghese, P. S., Riley, T. N., Miller, J. W.: Stereochemical studies on medicinal agents. X. The role of chirality in α-adrenergic receptor blockade by (+)-and (−)-phenoxybenzamine HCl. J. med. Chem. 14, 561–564 (1971).PubMedGoogle Scholar
  194. Pratesi, P.: Chemical structure and biological activity of catecholamines. Pure Appl. Chem. 6, 435–449 (1963); Pharmaceutical Chemistry Internat. Symposium on Pharmaceutical Chemistry (1962). London: Butterworths 1963.Google Scholar
  195. Pratesi, P., Blaschko, H.: Specificity of amine oxidase for optically active substrates and inhibitors. Brit. J. Pharmacol. 14, 256–261 (1959).PubMedGoogle Scholar
  196. Puri, S. K., O’Brien, J., Lal, H.: Potentiation of morphine-withdrawal agression by d-amphetamine dopa or apomorphine. Pharmacologist 13, 280 (1971).Google Scholar
  197. Rech, R. H., Stolk, J. M.: Amphetamine-drug interactions that relate brain catecholamines to behavior. In: Amphetamine and related compounds, p. 385–413, ed. by Costa, E., Garattini, S. New York: Raven Press 1970.Google Scholar
  198. Reuter, H., Wollert, U.: Über die Wirkung verschiedener sympathomimetischer Amine auf Kontraktionskraft und 45Ca-Aufnahme isolierter Meerschweinchenvorhöfe. Naunyn-Schmiedebergs Arch. Pharmak. exp. Path. 258, 288–296 (1967).Google Scholar
  199. Robak, J., Gryglewski, R.: Influence of propranolol, INPEA, iproveratril and some 1-naphthylethyl amine derivatives on the myocardial phosphorylase activity. Biochem. Pharmacol. 19, 1221–1227 (1970).PubMedGoogle Scholar
  200. Rossum, J. M. van: Mechanism of the central stimulant action of α-methyl-metatyrosine. Psychopharmacologia 4, 271–280 (1963).Google Scholar
  201. Roszkowski, A. P., Kelley, N. M.: A rapid method for assessing drug inhibition of feeding behavior. J. Pharmacol. exp. Ther. 140, 367–374 (1963).PubMedGoogle Scholar
  202. Roth, L. W., Richards, R. K., Shemano, I., Morphis, B. B.: A comparison of the analeptic, circulatory and other properties of d-and 1-desoxyephedrine. Arch. int. Pharmacodyn. 98, 362–368 (1954).PubMedGoogle Scholar
  203. Saari, W. S., Raab, A. W., Engelhardt, E. L.: The stereoisomers of α-(1-aminoethyl)-m-hydroxybenzyl alcohol. J. med. Chem. 11, 1115–1117 (1968).PubMedGoogle Scholar
  204. Sachs, C.: Noradrenaline uptake mechanisms in the mouse atrium, a biochemical and histochemical study. Acta physiol. scand., Suppl. 341, 1–57 (1970).Google Scholar
  205. Salvador, R. A., Colville, K. I., April, S. A., Burns, J. J.: Inhibition of lipid mobilization by N-isopropyl methoxamine (B.W. 61–43). J. Pharmacol. exp. Ther. 144, 172–180 (1964).PubMedGoogle Scholar
  206. Sapirstein, L. A., Andrews, R., Pultz, A., Ridolfo, A.: Effects of amphetamine and its isomers on excretion of sodium and water in the rat. Proc. Soc. exp. Biol. (N.Y.) 82, 609–612 (1953).PubMedGoogle Scholar
  207. Saunamaki, K. I.: Studies on the anti-arrhythmic effect of dextroalprenolol. Pharmacol. Clin. 3, 23–31 (1970).Google Scholar
  208. Scales, B., McIntosh, D. A. D.: Effect sof propranolol and its optical isomers on the radiocalcium uptake and the adenosine triphosphatases of skeletal and cardiac sarcoplasmic reticulum fractions (SRF). J. Pharmacol. exp. Ther. 160, 261–267 (1968).PubMedGoogle Scholar
  209. Schmidt, G., Kalischer, B., Wöckel, B.: Vergleichende Untersuchungen über die Wirkungen von Normal-Cocain und Pseudococain. Naunyn-Schmiedebergs Arch. exp. Path. Pharmak. 240, 523–538 (1961).Google Scholar
  210. Schultz, F. H.: The effect of cinnamylephedrine on smooth muscle. J. Pharmacol. exp. Ther. 70, 283–292 (1940).Google Scholar
  211. Seidehamel, R. J., Patil, P. N., Tye, A., LaPidus, J. B.: The effects of norepinephrine isomers on various supersensitivities of the cat nictitating membrane. J. Pharmacol. exp. Ther. 153, 81–89 (1966).PubMedGoogle Scholar
  212. Shafi’ee, A., Hite, G.: The absolute configurations of the pheniramines, methyl phenidates, and pipradrols. J. med. Chem. 12, 266–270 (1969).PubMedGoogle Scholar
  213. Sheppard, H., Burghardt, C. R.: The effect of alpha, beta, and dopamine receptor-blocking agents on the stimulation of rat erythrocyte adenyl cyclase by dihydroxyphenethylamines and their β-hydroxylated derivatives. Molec. Pharmacol. 7, 1–7 (1970).Google Scholar
  214. Shonk, R. F., Miller, D. D., Feller, D. R.: Influence of substituted tetrahydroisoquinolines and catecholamines on lipolysis, in vitro. II. Stereoselectivity. Biochem. Pharmacol. 20, 3403–3412 (1971).PubMedGoogle Scholar
  215. Shore, P. A., Alpers, H. S.: Fluorometric estimation of metaraminol and related amines. Life Sci. 3, 551–554 (1964).PubMedGoogle Scholar
  216. Shore, P. A., Alpers, H. S., Busfield, D.: On the mechanism of norepinephrine depletion by reserpine, metaraminol and related compounds and antagonism by monoamine oxidase inhibition, Mechanisms of release of biogenic amines, p. 319–329 (ed. by Euler, U. S. von, Rosell, S., Uvnäs, B.). Proc. of an Internat. Wenner-Gren Symposium 1966.Google Scholar
  217. Shore, P. A., Busfield, D., Alpers, H. S.: Binding and release of metaraminol: Mechanism of norepinephrine depletion by α-methyl-M-tyrisone and related agents. J. Pharmacol. exp. Ther. 146, 194–199 (1964).PubMedGoogle Scholar
  218. Siva Sankar, D. V.: Discriminatory in vitro effects of d-and l-amphatemines on alcohol dehydrogenases. Res. Commun. chem. pathol. Pharmacol. 1, 460–462 (1970).Google Scholar
  219. Slocum, D. W., Sugarman, D., Tucker, S. P.: Two faces of D and L nomenclature. J. chem. Educ. 48, 597–600 (1971).Google Scholar
  220. Smissman, E. E., Borchardt, R. T.: A conformational study of catecholamine receptor sites. 5. Syntheses of dl-3-amino-2-(3,4-dihydroxyphenyl)-trans-2-decalol hydrochlorides. J. med. Chem. 14, 377–382 (1971a).PubMedGoogle Scholar
  221. Smissman, E. E., Borchardt, R. T.: A conformational study of catecholamine receptor sites. 6. Syntheses of dl-3-amino-2-(3,4-dihydroxyphenyl)-trans-2-decalin hydrochloride. J. med. Chem. 14, 383–387 (1971b).PubMedGoogle Scholar
  222. Smissman, E. E., Gastrock, W. H.: A conformational study of β-phenethanolamine receptor sites. I. The syntheses of the 3-amino-2-phenyl-trans-2-decalols. J. med. Chem. 11, 860–864 (1968).PubMedGoogle Scholar
  223. Smissman, E. E., Vickers, S. J.: A conformational study of β-phenethanolamine receptor sites. IV. Synthesis of erythro-and threo-3-amino-2-phenyl-2-butanols. J. med. Chem. 13, 1224–1225 (1970).PubMedGoogle Scholar
  224. Snyder, S. H.: Putative neurotransmitters in the brain: selective neuronal uptake, subcellular localization, and interactions with centrally acting drugs. Biol. Psychiat. 2, 367–389 (1970).PubMedGoogle Scholar
  225. Somani, P.: Study on some selective β-adrenoreceptor blocking effects of 1-(4-nitrophenyl)-1-hydroxy-2-methyl isopropylaminoethane (α-methyl INPEA). Brit. J. Pharmacol. 37, 609–617 (1969).Google Scholar
  226. Somani, P., Watson, D. L.: Antiarrhythmic activity of the dextro-and levo-rotatory isomers of 4-(2-isopropylamino-1-hydroxyethyl) methanesulfonanilide (MJ 1999). J. Pharmacol. exp. Ther. 164, 317–325 (1968).PubMedGoogle Scholar
  227. Sourkes, T. L., Wiseman-Distler, M. H., Moran, J. F., Murphy, G. F., Saint, C. S.: Comparative metabolism of D and L, 3,4 dihydroxyphenylalanine in normal and pyridine-deficient rats. Biochem. J. 93, 469–474 (1964).PubMedGoogle Scholar
  228. Stelt, C. van der, Heus, W. J., Nauta, W. T.: The resolution in optical isomers of orphenadrine, 4-methyldiphenhydramine and their N-demethyl derivatives. Arzneimittel-Forsch. 12, 2010–2012 (1969).Google Scholar
  229. Stenlake, J. B., Breimer, D. D., Smail, G. A., Stafford, A., Bowman, W. C.: The preparation and properties of (+)-and (-)-guanoxan. J. Pharm. Pharmacol. 20, Suppl., 82–93 (1968).Google Scholar
  230. Stickney, J. L., Lucchesi, B. R.: The effect of sympatholytic agents on the cardiovascular responses produced by the injection of acetylstrophanthidin into the cerebral ventricles. Europ. J. Pharmacol. 6, 1–7 (1969).Google Scholar
  231. Stock, K., Westermann, E.: Competitive and non-competitive inhibition of lipolysis by α-and β-adrenergic blocking agents, methoxamine derivatives, and prostaglandin E1. Life Sci. 5, 1667–1678 (1966).Google Scholar
  232. Sugrue, M. F., Shore, P. A.: The mode of sodium dependency of the adrenergic neuron amine carrier. Evidence for a second, sodium-dependent, optically specific and reserpine-sensitive system. J. Pharmacol. exp. Ther. 170, 239–245 (1969).PubMedGoogle Scholar
  233. Sugrue, M. F., Shore, P. A.: Further evidence for a sodium-dependent, optically specific and reserpine-sensitive amine carrier mechanism at the adrenergic neuron. J. Pharmacol. exp. Ther. 177, 389–396 (1971).PubMedGoogle Scholar
  234. Swamy, V. C., Tye, A., LaPidus, J. B., Patil, P. N.: Steric aspects of adrenergic drugs. XIII. Norepinephrine potentiating effects of isomers of sympathomimetic amine in rat vas deferens and atria. Arch. int. Pharmacodyn. 182, 24–31 (1969).PubMedGoogle Scholar
  235. Swanson, E. E., Scott, C. C., Lee, H. M., Chen, K. K.: Comparison of the pressor action of some optical isomers of sympathomimetic amines. J. Pharmacol. exp. Ther. 79, 329–333 (1943).Google Scholar
  236. Symchowicz, S., Korduba, C. A., Veals, J.: Inhibition of dopamine uptake into synaptosomes of rat corpus striatum by chlorpheniramine and its structural analogues. Life Sci. 10, 35–42 (1971).Google Scholar
  237. Tagliamonte, A., Tagliamonte, P., Gessa, G. L.: Cross tolerance to the anorexigenic effect of d-amphetamine, l-amphetamine, fenfluramine and desmethylimipramine in rats. Pharmacologist 11, 264 (1969).Google Scholar
  238. Taylor, K. M., Snyder, S. H.: Amphetamine: Differentiation by d and 1 isomers of behavior involving brain norepinephrine or dopamine. Science 168, 1487–1489 (1970).PubMedGoogle Scholar
  239. Torchiana, M. L., Porter, C. C., Stone, C. A.: Relation between molecular configuration and certain biological actions of α-methyldopamine and α-methyl-meta-tyramine and their β-hydroxylated products α-methylnorepinephrine and metaraminol. Arch. int. Pharmacodyn. 174, 118–134 (1968).PubMedGoogle Scholar
  240. Torchiana, M. L., Wenger, H. C., Stavorski, J., Ludden, C. T., Stone, C. A.: Effect of methyldopa and related agents on pressor responses to tyramine in reserpine-pretreated rats and dogs. J. Pharmacol. exp. Ther. 151, 242–252 (1966).PubMedGoogle Scholar
  241. Trendelenburg, U.: Supersensitivity by cocaine to dextrorotatory isomers of norepinephrine and epinephrine. J. Pharmacol. exp. Ther. 148, 329–338 (1965).PubMedGoogle Scholar
  242. Trendelenburg, U.: Supersensitivity to norepinephrine induced by continuous nerve stimulation. J. Pharmacol. exp. Ther. 151, 95–102 (1966).PubMedGoogle Scholar
  243. Trendelenburg, U.: Supersensitivity of the isolated nictitating membrane of the cat to sympathomimetic amines after impairment of the intraneuronal mechanisms of inactivation. Naunyn-Schmiedebergs Arch. Pharmak. 271, 29–58 (1971).Google Scholar
  244. Trendelenburg, U., Draskóczy, P. R.: The effect of intraneuronal inactivation on the transmembranal uptake of 1-and d-norepinephrine. J. Pharmacol. exp. Ther. 175, 521–524 (1970).PubMedGoogle Scholar
  245. Tseng, L.-F., Walaszek, E. J.: Cardiovascular responses to dopamine in chickens. Pharmacologist 13, 248 (1971).Google Scholar
  246. Tye, A., Patil, P. N., LaPidus, J. B.: Steric aspects of adrenergic drugs. III. Sensitization by cocaine to isomers of sympathomimetic amines. J. Pharmacol. exp. Ther. 155, 24–30 (1967).PubMedGoogle Scholar
  247. Udenfriend, S.: Biosynthesis of the sympathetic neurotransmitter. The Harvey lectures series 60, p. 57. New York: Academic Press 1966.Google Scholar
  248. Vidrio, H., Parra, J., Pardo, E. G.: Characterization of the antihypertensive effects of d-methamphetamine. Fed. Proc. 29, 150 (1970).Google Scholar
  249. Waldeck, B.: On the interaction of threo-3H-α-methylnoradrenaline with the uptake and storage mechanisms of the adrenergic neuron. Europ. J. Pharmacol. 2, 208–213 (1967).Google Scholar
  250. Waldeck, B.: On the stereospecificity of the β-hydroxylation of α-methyldopamine. Europ. J. Pharmacol. 5, 114–116 (1968).Google Scholar
  251. Werner, U., Wagner, J., Schümann, H. J.: Beeinflussung der Noradrenalinabgabe aus isolierten Kaninchenherzen durch β-Adrenolytica unter sympathischer Nervenreizung. Naunyn-Schmiedebergs Arch. Pharmak. 268, 102–113 (1971).Google Scholar
  252. Westfall, T. C.: Uptake and exchange of catecholamines in rat tissues after administration of d-and 1-adrenaline. Acta physiol. scand. 63, 336–342 (1965).PubMedGoogle Scholar
  253. Wise, C. D., Stein, L.: Facilitation of brain self-stimulation by central administration of norepinephrine. Science 163, 299–301 (1969).PubMedGoogle Scholar
  254. Wolf, H. H., Rollins, D. E., Rowland, C. R., Reigle, T. G.: The importance of endogenous catecholamines in the activity of some CNS stimulants. Int. J. Neuropharmacol. 8, 319–328 (1969).PubMedGoogle Scholar
  255. Wolf, H. H., Schuster, M. A., Lanciault, G.: “Aggregation” phenomenon and some ephedrine isomers. J. pharm. Sci. 53, 987–988 (1964).PubMedGoogle Scholar
  256. Wong, S., Long, J. P.: Potentiation of actions of catecholamines by a derivative of hemicholinium. J. Pharmacol. exp. Ther. 156, 469–482 (1967).PubMedGoogle Scholar
  257. Woodruff, G. N., Walker, R. J.: The effect of dopamine and other compounds on the activity of neurones of helix aspersa; structure-activity relationships. Int. J. Neuropharmacol. 8, 279–289 (1969).PubMedGoogle Scholar
  258. Yamada, S., Terashima, S., Achiwa, K.: Absolute configuration of biochemically active (-)-a-methyl-3,4-dihydroxyphenylalanine. Chem. pharm. Bull. 13, 227–229 (1965).PubMedGoogle Scholar
  259. Yokel, R. A., Pickens, R.: Intravenous self-administration of dextro and levo isomers of amphetamine and methamphetamine by rats. Pharmacologist 13, 281 (1971).Google Scholar
  260. Zirkle, C. L., Kaiser, C., Tedeschi, D. H., Tedeschi, R. E., Burger, A.: 2-Substituted cyclopropylamines. II. Effect of structure upon monoamine oxidase-inhibitory activity as measured in vivo by potentiation of tryptamine convulsions. J. med. Chem. 5, 1262–1284 (1962).Google Scholar

Copyright information

© Springer-Verlag 1972

Authors and Affiliations

  • P. N. Patil
    • 1
  • J. B. LaPidus
    • 2
  1. 1.College of PharmacyThe Ohio State UniversityColumbusUSA
  2. 2.Graduate SchoolColumbusU. S. A.

Personalised recommendations